PDCD1 and neoplasm: Increasing tumour oxygen levels by either supplemental oxygenation or treatment with a hypoxia-activated pro-drug has been shown to improve the response to anti-PD-1 and anti-CTLA-4 in cancer models, through undefined mechanisms linked to enhanced CD8+ T cell-mediated immunity [3, 4].